We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
- Authors
Paltiel, A David; Freedberg, Kenneth A; Scott, Callie A; Schackman, Bruce R; Losina, Elena; Wang, Bingxia; Seage, George R, 3rd; Sloan, Caroline E; Sax, Paul E; Walensky, Rochelle P
- Abstract
The combination of tenofovir and emtricitabine shows promise as HIV preexposure prophylaxis (PrEP). We sought to forecast clinical, epidemiologic, and economic outcomes of PrEP, taking into account uncertainties regarding efficacy, the risks of developing drug resistance and toxicity, behavioral disinhibition, and drug costs.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Vol 48, Issue 6, p806
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/597095